Day: January 9, 2023

AmmPower Corp. Completes Acquisition of 50.05% of the Common Shares of Progressus Clean Technologies, Inc.

Written by Customer Service on January 9, 2023. Posted in Mergers And Acquisitions.

TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) — AmmPower Corp. (CSE:AMMP, OTCQB:AMMPF, FSE:601A) (the “Company” or “AmmPower“) is pleased to announce, further to its news release dated December 30, 2022, that it has completed the acquisition (the “Acquisition”) of 50.05% of the issued and outstanding common shares of Progressus Clean Technologies, Inc. (“Progressus”), from certain former shareholders of Progressus (the “Vendors”). In consideration for the Acquisition, the Company issued an aggregate of 50,000,000 common shares in the capital of the Company (the “Company Shares”) to the Vendors at a deemed price of C$0.30 per Company Share. In connection with the Acquisition, the Vendors agreed to provide to the Company an aggregate loan of $500,000 payable as follows: (a) $250,000 provided on January 6, 2023 (the...

Royalty Pharma Announces Dividend Increase

Written by Customer Service on January 9, 2023. Posted in Dividend Reports And Estimates.

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2023 of $0.20 per Class A share, reflecting a 5.3% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 15, 2023 to shareholders of record at the close of business on February 16, 2023. “We are pleased to once again announce an increase to our dividend,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We are committed to returning capital to our shareholders through our attractive dividend while retaining financial flexibility to fund innovation. We continue to see significant opportunities for value-enhancing growth as the demand for capital in the biopharma ecosystem...

Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting

Written by Customer Service on January 9, 2023. Posted in Public Companies.

Topline safety, antiviral effectiveness and pharmacokinetic (PK) data from a Phase 1b Study in China are released from the single ascending dose (SAD) portion of the study with the doses from 300 mg to 2,000 mg in 32 healthy volunteers and the multiple ascending dose (MAD) portion of the study in 46 COVID-19 patients with 300 mg BID, 600 mg BID and 800 mg BID daily dosing for 7.5 days. Overall, STI-1558 was well-tolerated at all doses tested, with most subjects in both the SAD and MAD portions of the study reporting no adverse events (AEs). There was no dose limiting toxicity during the study. There were no severe or serious AEs, no premature discontinuations of STI-1558 due to an AE, and no deaths. Most AEs were mild, unrelated and required no medical treatment. In the MAD portion of the study (n=41 evaluable), COVID-19 patients (n=29)...

Medigus: Eventer Technologies Signed a Definitive Agreement for Reverse Merger to Become a Public Company

Written by Customer Service on January 9, 2023. Posted in Mergers And Acquisitions.

Eventer will merge with a Tel-Aviv Stock Exchange listed company following which Eventer shareholdres will hold 74.99% of the merged company Tel Aviv, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that its 46.21% owned subsidiary, Eventer Technologies Ltd. (“Eventer”), a software company engaged in the development of platforms enabling producers and venues to create virtual conferences and events including a smart ticketing solution, signed a definitive agreement (“Agreement”) for a planned securities exchange with AI Conversation Systems Ltd. (TASE: AICS) (“AI Conversation Systems”), an Israeli company traded on the...

Consolidated Water Acquires Remaining 39% Interest in PERC Water Corporation for $7.8 Million

Written by Customer Service on January 9, 2023. Posted in Mergers And Acquisitions.

GEORGE TOWN, Grand Cayman, Jan. 09, 2023 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading developer and operator of advanced water supply and treatment plants, has exercised its option to purchase the remaining 39% equity ownership in its subsidiary, PERC Water Corporation (PERC), for approximately $7.8 million, comprised of $2.44 million in cash and 368,383 shares of common stock valued at approximately $5.36 million. Headquartered in Fountain Valley, California, PERC is a leading water infrastructure company that designs, builds, and operates water and wastewater infrastructure throughout the Western U.S. As a result of the transaction completed on January 4, 2023, Consolidated Water became the 100% owner of PERC. PERC generated revenues of approximately $17.8 million in the first...

Ace Global Business Acquisition Limited Announces Extension of Combination Period and Additional Contribution to Trust Account to Extend Combination Period

Written by Customer Service on January 9, 2023. Posted in Mergers And Acquisitions.

New York, Jan. 09, 2023 (GLOBE NEWSWIRE) — Ace Global Business Acquisition Limited (NASDAQ: ACBA, the “Company”), a special purpose acquisition company, announced today that at its annual general meeting of shareholders on January 5, 2023 (the “Meeting”), the Company’s shareholders voted in favor of the proposal to amend its memorandum and articles of association, giving the Company the right to extend the date by which the Company has to complete a business combination (the “Combination Period”) a total of five (5) times, as follows: (i) two (2) times for an additional three (3) months each time from January 8, 2023 to July 8, 2023, followed by (ii) three (3) times for an additional one (1) month each time from July 8, 2023 to October 8, 2023. On January 5, 2023, Ace Global Investment Limited, the Company’s initial public offering...

Navient to announce fourth quarter 2022 results on Jan. 24, host earnings webcast on Jan. 25

Written by Customer Service on January 9, 2023. Posted in Earnings Releases And Operating Results.

WILMINGTON, Del., Jan. 09, 2023 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI), a leader in technology-enabled education finance and business processing solutions, plans to release its 2022 fourth quarter financial results on Navient.com/investors after market close on Tuesday, Jan. 24, 2023. Navient also will host an audio webcast to review results on Wednesday, Jan. 25, 2023, at 8 a.m. Eastern Time. Analysts and investors who wish to ask questions are requested to pre-register at Navient.com/investors anytime ahead of the webcast or at least 15 minutes ahead of start time to receive their personal dial-in access details. Others who wish to join in listen-only mode do not need to pre-register and may simply visit Navient.com/investors to access the webcast. Supplemental financial information and presentation slides used during the...

AmeriCann Reports Record Fiscal Year-End and Quarterly Financial Results

Written by Customer Service on January 9, 2023. Posted in Earnings Releases And Operating Results.

The Company achieved all-time revenue, record net income and substantial EBITDA growth BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) — via InvestorWire — AmeriCann Inc. (OTCQB: ACAN) (the “Company”), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, released financial and operational results for its fiscal year and quarter ending September 2022. “Our focus on cost efficiency has produced some of the strongest adjusted operating EBITDA margins in the industry,” said CFO Ben Barton. “We look forward to investing the cash flow we are generating to further expand operations at the Massachusetts Cannabis Center and to produce even better financial results for shareholders. Financial Overview The Company achieved four consecutive quarters of increased operating revenue, culminating...

Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

Written by Customer Service on January 9, 2023. Posted in Earnings Releases And Operating Results.

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, representing an increase of 42% and 8% over the same periods last year. The fourth quarter growth rate reflects benefits from the Company’s commercial team expansion and focused sales strategy, as well as continued market traction in line with the Company’s penetration of market segments beyond heart failure patients. The fourth quarter revenue by segment was led by Pediatrics, followed by Heart Failure...

SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

Written by Customer Service on January 9, 2023. Posted in Public Companies.

Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKRT DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) — SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has submitted an investigational device exemption (IDE) application to the U.S. Food and Drug Administration (FDA) requesting approval to initiate a pivotal study to evaluate the effectiveness of the Company’s Selective Cytopheretic Device (SCD) in reducing hyperinflammation in adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT). The randomized, controlled study is expected to enroll 200 subjects, with a primary endpoint of a composite of 90-day mortality...

Day: January 9, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals